Kazan
RUSSIAN FEDERATION
10-11 JUNE 2019
Venue: Kazan, st. Peterburgskaya, 1, Grand Hotel Kazan.
Co-chairs
Andrés Cervantes, Spain
Alexey Tryakin, Russia
Faculty
Mona Frolova, Russian Federation
Giuseppe Curigliano, Italy
Andrés Cervantes, Spain
Rolf A. Stahel, Switzerland
Christos Sotiriou, Belgium
Domenica Lorusso, Italy
Sergei Tjulandin, Russian Federation
Fedor Moiseenko, Russian Federation
Alexey Smolin, Russian Federation
Ilya Pokataev, Russian Federation
Alexandra Tyulyandina, Russian Federation
Alexey Tryakin, Russian Federation
Learning Objectives
Accreditation
The programme of this event has been accredited with 13 ESMO-MORA Category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.
PROGRAMME
Monday, 10th June 2019
Hall «Gabdulla Tukay»
08:00 – Registration
Welcome & Introduction
08:20-08:30 – Welcome Address
Andre's Cervantes, Spain, and Alexey Tryakin, Russia
08:30-08:40 – Welcome from the chief oncologists of the Russian Federation
Ivan Stilidi, Russia, and Andrey Kaprin, Russia
08:40-08:50 – Welcome from the local Committee (Republic of Tatarstan)
Marat Sadykov, Russia, and Rustem Khasanov, Russia
08:50-08:55 – Introduction by ESMO Educational Committee Chair
Andre's Cervantes, Spain
08:50-09:00 – Introduction by RUSSCO Сhair
Sergei Tjulandin, Russia
SESSION 1. Breast Cancer
Chair:
Giuseppe Curigliano, Italy
Mona Frolova, Russia
09:00-09:30 – Current standards and practice changing studies in Early Breast Carcinoma
Giuseppe Curigliano, Italy
09:30-10:00 – Current standards and practice changing studies in Advanced HER2-positive and Triple Negative Breast carcinoma
Christos Sotiriou, Belgium
10:00-10:30 – Current standards and practice changing studies in Advanced HR-positive Breast Cancer
Mona Frolova, Russia
10:30-10:40 – Q&A
10:40-11:00 – Coffee break
11:00-12:00 – Clinical cases presentation
Elena Glazkova, Russia
Ramazan Iskenderov, Russia
Alfiya Khasanova, Russia
12:00-12:15 – Panel discussion
Hall «Gabdulla Tukay»
12:30-13:30 – AstraZeneka satellite symposia
12:30-12:35 – Opening remarks
Sergei Tjulandin, Russia
12:35-12:55 – Newly identified BRCA-associated ovarian cancer – is it possible not to wait for a relapse?
Svetlana Khokhlova, Russia
12:55-13:10 – Recurrence of ovarian cancer beyond the BRCA mutations
Alexandra Tyulyandina, Russia
13:10-13:25 – BRCA-associated breast cancer
Ludmila Zhukova, Russia
13:25-13:30 – Discussion. Closing remarks
Sergei Tjulandin, Russia
* Not covered by NMO
13:30-13:45 – Coffee break
SESSION 2. Gynaecological Cancer
Chair:
Domenica Lorusso, Italy
Alexandra Tyulyandina, Russia
13:45-14:15 – Current standards and practice changing studies in Ovarian Carcinoma
Alexandra Tyulyandina, Russia
14:15-14:45 – Current standards and practice changing studies in Endometrial Carcinoma
Domenica Lorusso, Italy
14:45-15:15 – Current standards and practice changing studies in Cervical Carcinoma
Domenica Lorusso, Italy
15:15-15:25 – Q&A
15:25-15:45 – Coffee break
15:45-16:45 – Clinical cases presentation
Aleksey Rumyantsev, Russia
Dmitriy Utkin, Russia
Gulnara Mukhamediarova, Russia
16:45-17:00 – Panel discussion
Hall «Gabdulla Tukay»
17:15-18:15 – Bayer satellite symposia
Bayer satellite symposia
Chairman:
Valery Breder, Russia
17:15-17:20 – Introduction by Chairman
17:20-17:45 – HCC treatment paradigm: looking for optimal decisions
Valery Breder, Russia
17:45-18:10 – Therapy algorithm for pre-treated patients with mCRC
Mikhail Fedyanin, Russia
18:10-18:15 – Q&A section
Valery Breder, Russia
* Not covered by NMO
Hall «Salikh Saydashev»
17:15-18:15 – Pfizer satellite symposia
Pfizer satellite symposia
Chairman:
Ludmila Zhukova, Russia
17:15-17:35 – CDK 4/6 inhibitors contribution to achieving HR+ HER2– mBC treatment goals
Marina Stenina, Russia
17:35-17:50 – Tolerability of combined therapy with CDK 4/6 inhibitors and monitoring aspects
Ludmila Zhukova, Russia
17:50-18:10 – Case study: treatment decision making and management in patients with HR+ HER2- mBC
Irina Koroleva, Russia
18:10-18:15 – Questions and answers
* Not covered by NMO
Tuesday, 11th June 2019
Hall «Gabdulla Tukay»
SESSION 3. Lung Cancer
Chair:
Rolf A. Stahel, Switzerland
Fedor Moiseenko, Russia
09:00-09:20 – Current standards and practice changing studies in NSCLC stage I-III
Rolf A. Stahel, Switzerland
09:20-09:50 – Current standards and practice changing studies in metastatic NSCLC without actionable mutations
Fedor Moiseenko, Russia
09:50-10:20 – Current standards and practice changing studies in metastatic NSCLC with actionable mutations
Rolf A. Stahel, Switzerland
10:20-10:35 – Coffee break
10:35-10:55 – Current standards and practice changing studies in SCLC
Alexey Smolin, Russia
10:55-11:10 – Q&A
11:10-12:10 – Clinical cases presentation
Elizaveta Artem'yeva, Russia
Rafael Enickeev, Russia
12:10-12:25 – Panel discussion
Hall «Gabdulla Tukay»
12:40-13:40 – AstraZeneka satellite symposia
AstraZeneka symposium
Moderator:
Konstantin Laktionov, Russia
12:40-12:45 – Introduction
Konstantin Laktionov, Russia
12:45-13:00 – Unresectable stage III of NSCLC. How can we achieve the maximum efficacy of CRT?
Natalia Dengina, Russia
13:00-13:20 – Innovative approaches in treatment of patients with unresectable stage III of NSCLC
Konstantin Laktionov, Russia
13:20-13:35 – Immunotherapy implementation in combination with CRT in stage III NSCLC in clinical practices
Olga Goncharova, Russia
13:35-13:40 – Q&A session
Konstantin Laktionov, Russia
* Not covered by NMO
Hall «Salikh Saydashev»
12:40-13:40 – MSD satellite symposia
MSD satellite symposia
Chairman:
O.A. Gladkov, Russia
Immunotherapy for NSCLC treatment: what else to consider except for PD-L1 expression?
F.V. Moiseenko, Russia
Immunotherapy for MSI-H tumors: when to test for MSI-H?
O.A. Gladkov, Russia
* Not covered by NMO
Hall «Adel' Kutuy»
12:40-13:40 – BMS satellite symposia
Chairman:
Alexey Tryakin, Russia
Nivolumal as a backbone for combination immunotherapy in solid tumors:
12:40-12:55 – In metastatic melanoma
Galina Kharkevich, Russia
12:55-13:10 – In lung cancer
Alexey Smolin, Russia
13:10-13:25 – In oncourology
Maria Volkova, Russia
13:25-13:40 – In GI tumors
Alexey Tryakin, Russia
* Not covered by NMO
13:40-14:00 – Coffee break
SESSION 4. GI Cancers
Chair:
Andrés Cervantes, Spain
Ilya Pokataev, Russia
14:00-14:30 – Current standards and practice changing studies in Pancreatic and Hepatic Carcinoma
Ilya Pokataev, Russia
14:30-15:00 – Current standards and practice changing studies in Esophageal and Gastric Carcinoma
Alexey Tryakin, Russia
15:00-15:30 – Current standards and practice changing studies in Advanced Colon Carcinoma
Andrés Cervantes, Spain
15:30-15:40 – Q&A
15:40-16:00 – Coffee break
16:00-16:20 – Current standards and practice changing studies in Localized Rectal Cancer
Andrés Cervantes, Spain
16:20-17:20 – Clinical cases presentation
Elizaveta Polyanskaya, Russia
Anna Popova, Russia
Sergey Belukhin, Russia
17:20-17:40 – Panel discussion
17:40-18:00 – Adjourn and Close Remarks
